If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its ...

The letters demand US drug prices match or undercut global lows, triggering a 60-day compliance timeline, and prompting ...